Revolution Medicines, Inc. (RVMD) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $21.00K; Additional Paid in Capital, Common StockUSD $6.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-5.95M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $19.00K; Additional Paid in Capital, Common StockUSD $4.82B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-622.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $19.00K; Additional Paid in Capital, Common StockUSD $4.50B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $3.24M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $4.10B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $3.12M.
Revolution Medicines, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $21.00K | $6.58B | $-5.95M | $-3.97B | $2.61B | 3 month · $67.00M | (m) |
| 2026-03-31 | $0.00 | $19.00K | $4.82B | $-622.00K | $-3.32B | $1.50B | 3 month · $87.30M | (m) |
| 2025-12-31 | $0.00 | $19.00K | $4.50B | $3.24M | $-2.87B | $1.63B | 12 month · $118.39M | (m) |
| 2025-09-30 | $0.00 | $18.00K | $4.10B | $3.12M | $-2.50B | $1.60B | 3 month · $30.78M | (m) |
| 2025-06-30 | $0.00 | $18.00K | $4.06B | $1.30M | $-2.20B | $1.87B | 3 month · $28.83M | (m) |
| 2025-03-31 | $0.00 | $18.00K | $4.03B | $1.71M | $-1.95B | $2.08B | 3 month · $25.08M | (m) |
| 2024-12-31 | $0.00 | $18.00K | $4.00B | $1.32M | $-1.74B | $2.27B | 12 month · $79.20M | 12 month · $95.42M |
| 2024-09-30 | $0.00 | $16.00K | $3.11B | $3.81M | $-1.54B | $1.57B | 3 month · $20.77M | (m) |
| 2024-06-30 | $0.00 | $16.00K | $3.01B | $-1.86M | $-1.39B | $1.62B | 3 month · $19.77M | (m) |
| 2024-03-31 | $0.00 | $16.00K | $2.98B | $-1.20M | $-1.25B | $1.73B | 3 month · $16.21M | (m) |
| 2023-12-31 | $0.00 | $16.00K | $2.96B | $544.00K | $-1.14B | $1.83B | 12 month · $61.77M | (m) |
| 2023-09-30 | $0.00 | $11.00K | $1.81B | $-871.00K | $-976.17M | $837.46M | 3 month · $13.67M | (m) |
| 2023-06-30 | $0.00 | $11.00K | $1.80B | $-1.25M | $-867.74M | $930.84M | 3 month · $12.98M | (m) |
| 2023-03-31 | $0.00 | $11.00K | $1.72B | $-556.00K | $-769.44M | $952.22M | 3 month · $9.70M | (m) |
| 2022-12-31 | $0.00 | $9.00K | $1.39B | $-1.78M | $-701.34M | $685.19M | 12 month · $31.20M | (m) |
| 2022-09-30 | $0.00 | $9.00K | $1.33B | $-2.42M | $-644.83M | $681.42M | 3 month · $8.14M | (m) |
| 2022-06-30 | $0.00 | $8.00K | $1.07B | $-1.76M | $-571.50M | $498.84M | 3 month · $8.10M | (m) |
| 2022-03-31 | $0.00 | $8.00K | $1.06B | $-1.28M | $-510.28M | $550.99M | 3 month · $6.64M | (m) |
| 2021-12-31 | $0.00 | $8.00K | $1.06B | $-376.00K | $-452.64M | $602.57M | 12 month · $20.72M | (m) |
| 2021-09-30 | (m) | $8.00K | $1.04B | $-40.00K | $-399.96M | $638.20M | 3 month · $5.83M | (m) |
| 2021-06-30 | (m) | $8.00K | $1.03B | $9.00K | $-347.02M | $685.01M | 3 month · $5.31M | (m) |
| 2021-03-31 | (m) | $8.00K | $1.03B | $63.00K | $-302.72M | $722.58M | 3 month · $3.39M | (m) |
| 2020-12-31 | (m) | $7.00K | $740.10M | $116.00K | $-265.55M | $474.68M | 12 month · $8.89M | (m) |
| 2020-09-30 | (m) | $7.00K | $736.19M | $211.00K | $-231.34M | $505.07M | 3 month · $2.67M | (m) |
| 2020-06-30 | (m) | $6.00K | $564.32M | $291.00K | $-204.12M | $360.50M | 3 month · $2.02M | (m) |
| 2020-03-31 | (m) | $6.00K | $562.18M | $36.00K | $-176.91M | $385.32M | 3 month · $1.57M | (m) |
| 2019-12-31 | (m) | (m) | $4.74M | $74.00K | $-157.39M | $-152.57M | 12 month · $3.16M | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-139.45M | 3 month · $854.00K | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-127.70M | 3 month · $506.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-118.11M | 3 month · $403.00K | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-108.42M | 12 month · $855.00K | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-67.72M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |